M
Mauricio Tohen
Researcher at University of New Mexico
Publications - 476
Citations - 34199
Mauricio Tohen is an academic researcher from University of New Mexico. The author has contributed to research in topics: Bipolar disorder & Olanzapine. The author has an hindex of 95, co-authored 464 publications receiving 32214 citations. Previous affiliations of Mauricio Tohen include University of Minnesota & University of Alabama at Birmingham.
Papers
More filters
Journal ArticleDOI
Telephone versus in-person clinical and health status assessment interviews in patients with bipolar disorder.
Dennis A. Revicki,Mauricio Tohen,Laszlo Gyulai,Christine L. Thompson,Stephanie Pike,Annette Davis-Vogel,Carlos A. Zarate +6 more
TL;DR: Phone interviews are feasible and reliable for collecting data on psychiatric and other health‐related outcomes in bipolar disorder patients and indicate good to excellent agreement on measures of mania and depression symptoms.
Journal ArticleDOI
DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.
TL;DR: These analyses support the validity of proposed DSM-5 criteria and confirm that depressive features are frequent in bipolar patients with manic episodes.
Journal ArticleDOI
Antipsychotic agents in the treatment of bipolar mania
Mauricio Tohen,Eduard Vieta +1 more
TL;DR: Evidence exists on the efficacy of both typical and atypical antipsychotics on the treatment of acute mania such that they are now clearly first-line along with lithium.
Journal ArticleDOI
Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial.
Lizheng Shi,M. Namjoshi,Ralph Swindle,Ralph Swindle,Xiaomin Yu,R.C. Risser,Robert W. Baker,Mauricio Tohen,Mauricio Tohen +8 more
TL;DR: Based on these analyses, patients with bipolar depression receiving olanzapine or OFC for 8 weeks had greater improvement in HRQOL than those receiving placebo, and correlation results support the construct validity of the QLDS.
Journal ArticleDOI
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
TL;DR: It was found that no baseline manic/hypomanic symptom of mixed depression predicted treatment response, and a higher number of baseline concurrent manic/ Hypomanic symptoms predicted a lower response rate in the olanzapine and placebo arms, but not in the OFC arm.